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Background: RNA-binding proteins regulate a number of cellular processes, including synthesis, folding,
translocation, assembly and clearance of RNAs. Recent studies have reported that an unexpectedly large number of
proteins are able to interact with RNA, but the partners of many RNA-binding proteins are still uncharacterized.
Results: We combined prediction of ribonucleoprotein interactions, based on catRAPID calculations, with analysis of
protein and RNA expression profiles from human tissues. We found strong interaction propensities for both
positively and negatively correlated expression patterns. Our integration of in silico and ex vivo data unraveled two
major types of protein–RNA interactions, with positively correlated patterns related to cell cycle control and
negatively correlated patterns related to survival, growth and differentiation. To facilitate the investigation of
protein–RNA interactions and expression networks, we developed the catRAPID express web server.
Conclusions: Our analysis sheds light on the role of RNA-binding proteins in regulating proliferation and
differentiation processes, and we provide a data exploration tool to aid future experimental studies.Background
With the advent of high-throughput proteomic and
transcriptomic methods, genome-wide data are giving
previously unprecedented views of entire collections of
gene products and their regulation. Recently, approaches
based on nucleotide-enhanced UV cross-linking and
oligo(dT) purification have shown that a number of pro-
teins are able to bind to RNA [1,2].
RNA-binding proteins (RBPs) are key regulators of
post-transcriptional events [3] and influence gene ex-
pression by acting at various steps in RNA metabolism,
including stabilization, processing, storing, transport and
translation. RBP-mediated events have been described
using recognition and regulatory elements in RNA
sequences [4,5] as well as expression profiles [6] that
are tissue specific and conserved across species [7-9].
Although heterogeneity in gene regulation is responsible
for phenotypic variation and evolution [10], very little is* Correspondence: gian.tartaglia@crg.es
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reproduction in any medium, provided the orknown about constitutive expression patterns controlled
by RBPs [11,12], which are the subject of this work.
Data from recent transcriptomic and proteomic
studies [13,14] are becoming attractive for studying
mechanisms of gene regulation [15,16]. Despite the
increasing amount of genomic data, the development
of computational methods for integrating, interpreting
and understanding molecular networks remains challen-
ging [17,18]. Here we combine our predictions of
protein–RNA interactions, based on catRAPID calcula-
tions [19,20], with the information obtained from
expression data to investigate constitutive regulatory
mechanisms. The catRAPID approach has been previously
employed to predict protein associations with non-coding
RNAs [21,22] as well as ribonucleoprotein interactions
linked to neurodegenerative diseases [23,24]. Our theoret-
ical framework has been used to unravel self-regulatory
pathways controlling gene expression [25]. The catRAPID
omics algorithm, validated using photoactivatable-ribonu-
cleoside-enhanced cross-linking and immunoprecipitation
(PAR-CLIP) data, has been recently developed to predict
protein–RNA associations at the transcriptomic and
proteomic levels [26].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of expression profiles in human tissues, at both protein
and RNA levels, we investigated the correlation between
RBP activity and regulation. The link between interaction
propensity and expression levels was exploited to reveal
the fine-tuned functional sub-networks responsible for
regulatory control. To explore the results further, we
developed the catRAPID express web server [27].
Results
In this study, we focused on the mRNA interactomes
of RBPs detected through nucleotide-enhanced UV
cross-linking and oligo(dT) purification approaches [1,2].
Exploiting gene ontology (GO) annotations [28] for
protein-coding genes, we systematically analyzed protein–
RNA interactions and expression data for human tissues.
At present, few studies have investigated how altering
protein expression affects the abundance of RNA targets.
Interrogating the Gene Expression Omnibus (GEO) [29]
and ArrayExpress databases [30], we found two human
proteins, ELAV-like protein 1 (or human antigen R,
HuR) [31] and Protein lin-28 homolog B (LIN28B)
[32,33], whose knock-down has been shown to alter
the expression of target genes identified by PAR-CLIP
(see Materials and methods).
Our predictions, made using the catRAPID algorithm
[26], identified experimentally validated interactions with
high significance (HuR: P = 10-8; LIN28B: P = 10-3; Fish-
er’s exact test; see Materials and methods). The interac-
tions were effectively discriminated from non-interacting
pairs using score distributions (LIN28B: P = 10-4; HuR:
P = 10-16; Student’s t-test; see Materials and methods).
Hence, catRAPID is very good at predicting physical in-
teractions between a protein and RNA partners (otherFigure 1 Relation between protein and RNA regulation. (A) HuR intera
expression levels of RNA targets change upon HuR knock-down (log-fold c
Kolmogorov–Smirnov test). (B) LIN28B interactome: RNA targets are downr
study [33] (P < 10-2; Kolmogorov–Smirnov test). In this analysis, the predictio
P < 10-3; Fisher’s exact test). Our results indicate that changes in protein exp
HuR, human antigen R; LFC, log-fold change; LIN28B, lin-28 homolog B.statistical tests are given in Materials and methods and
Additional file 1).
To understand the regulation of HuR and LIN28B
targets better, we studied the relation between inter-
action propensities and expression levels. We found
that the expression of predicted HuR targets is altered
(log-fold change, LFC) when HuR is knocked down
(P < 10-5; Kolmogorov–Smirnov test; Figure 1A), which
is in agreement with experimental data [31]. Similarly,
predicted LIN28B targets are downregulated upon
protein depletion (P < 10-2; Kolmogorov–Smirnov test;
Figure 1B), as shown in a previous study [33]. Moreover,
we compared the top 1% of predicted associations with
the top 1% of experimental interactions and found the
same enrichments for transcripts changing in expression
levels upon protein depletion. Specifically, 62% of HuR
experimental interactions and 63% of HuR predicted
associations had LFC > 0. Similarly for LIN28B, 57% of
experimental interactions and 56% of predicted associa-
tions had LFC > 0.
These HuR and LIN28B examples indicate that
changes in protein expression influence the abundance
of RNA targets, suggesting that a large-scale analysis
of co-expression and interaction propensities could
improve understanding of RBP-mediated regulatory
mechanisms.
RNA-binding protein–mRNA interactions and relative
expression profiles
Our predictions indicate that interacting molecules have
both more correlated and anti-correlated expression
patterns (see Materials and methods and Figure 2). By
contrast, non-correlated expression is not associated
with any enrichment in interaction propensity (Additionalctome: our predictions, made using catRAPID [26], indicate that
hanges, LFC), in agreement with experimental evidence [31] (P < 10-5;
egulated upon LIN28B knock-down (LFC), as reported in a previous
n of the interactions was highly significant (HuR: P < 10-8; LIN28B:
ression influence the abundance of RNA targets to a significant extent.
Figure 2 Protein–RNA interaction and expression. (A) In this analysis, we compared interacting and non-interacting protein–RNA pairs at
different interaction propensity scores. Areas under the curve (AUCs), expressed as percentages, were used to select the same number of interacting
and non-interacting protein–RNA pairs. (B) The same procedure was used to investigate positively and negatively correlated protein–RNA
expression at different thresholds. (C) With respect to non-interacting protein–RNA pairs, the predicted associations had enriched positively
correlated expression (that is, co-expression; see Materials and methods). (D) Compared to non-interacting protein–RNA pairs, the predicted
associations had enriched negatively correlated expression (that is, anti-expression; see Materials and methods). Non-correlated protein–RNA
expression did not show any similar trend (Additional file 1). AUC, area under the curve.
Cirillo et al. Genome Biology 2014, 15:R13 Page 3 of 12
http://genomebiology.com/2014/15/1/R13file 2: Figure S1A). We observed the same results using
immunohistochemistry [34] and RNA sequencing data [6]
to estimate protein abundances (Additional file 2: Figures
S1B and S2; see Materials and methods). This finding is
truly remarkable. Direct proportionality between protein
and mRNA expression levels has been observed in bac-
teria and fungi [13,14] but post-transcriptional modifica-
tion is known to influence the overall abundance of the
protein product in higher eukaryotes [35]. Since immuno-
histochemistry only provides a qualitative estimate of the
amount of protein (see Materials and methods) and the
analysis is restricted to 612 proteins, we used RNA se-
quencing for our predictions (1,156 RBPs).
The enrichment shown in Figure 2 suggests that a
good relation exists between interaction and expression
of protein–RNA molecules, which should have co-evolved to be either co-expressed or anti-expressed to
exert a regulatory function (Figure 2C,D).
Conservation of expression pattern for functionally
related genes
We classified protein–RNA associations into four categor-
ies: interacting and co-expressed (IC), interacting and
anti-expressed (IA), non-interacting and co-expressed
(NIC) and non-interacting and anti-expressed (NIA). We
applied conditional tests on each subset to detect signifi-
cantly over-represented gene ontology (GO) terms (see
Materials and methods and Additional file 3: Table S1).
For high interaction propensities, transcripts in the IC
subset have more processes associated with cell cycle
control, in particular the negative regulation of prolifera-
tion (Discussion; Additional file 3: Table S1).
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(IA subset) are involved in survival, growth and differen-
tiation processes and have more regulative functions at
the DNA level (Discussion; Additional file 3: Table S1).
No clear functional assignments and/or insufficiently
populated GO terms were found for transcripts in non-
interacting protein–RNA pairs (NIC and NIA subsets).Intrinsic disorder and RNA-binding protein interaction
propensity
Recent findings suggest that RBPs have more structurally
disordered regions [1]. To investigate the relation be-
tween disorder and RNA-binding ability, we used the
IUPred algorithm [36]. For each protein, we extracted
structurally disordered regions (IUPred score > 0.4 [1])
and calculated the interaction propensities with human
transcripts. We considered both canonical RBPs (that is,
containing RNA-binding domains) and putative RBPs
(that is, lacking RNA-binding domains) [1]. With respect
to the RNA-binding ability of full-length sequences, the
contribution of disorder is higher at low interaction pro-
pensity scores and becomes negligible at high interaction
propensities (see Materials and methods and Figure 3A).
Nevertheless, the role of structural disorder is more
pronounced in proteins lacking canonical RNA-bindingFigure 3 RNA-binding ability and structural disorder. (A) For each prot
well as structurally disordered regions [1,36]. When the interaction propens
(points above the red line), disorder is considered to promote interaction w
contributes at low interaction propensities, while full-length protein sequen
Overall, from low to high interaction propensities, the contribution of disor
protein (red and grey lines), in agreement with a previous analysis [25]. The
RNA-binding domains (grey line), indicating that unstructured regions migh
are averaged per protein. RBD, RNA-binding domain.domains, indicating that unfolded regions might be able
to promote interactions with RNA (Figure 3B).
In a previous study we observed that catRAPID scores
correlate with chemical affinities [21], which suggests
that the interaction propensity can be used to estimate
the strength of association [21,26]. Hence, our results in-
dicate that structural disorder might contribute to low-
affinity interactions with RNA (Figure 3A,B), which is in
agreement with what has been observed for protein–
protein associations [37,38]. As a matter of fact, it has
been reported that disorder regions are able to promote
promiscuous and non-specific interactions [39].Discussion
Because they are associated with transcriptional control
of gene expression, RBPs play fundamental roles in
health and disease. Indeed, by binding to their target
mRNAs, RBPs can influence protein production at dif-
ferent levels (transcription, translation and protein/
mRNA degradation). Protein–RNA complexes are very
dynamic and can undergo extensive remodeling. Thus,
they can control the spatiotemporal regulation of target
gene expression and the overall switching on and off of
the distinct sets of genes involved in biological processes
such as cell cycle progression, cell differentiation, cellein, we calculated RNA interactions with full-length sequences as
ity score of a disordered region exceeds that of the full-length protein
ith RNA molecules. (B) For 66% of the proteins (137 entries), disorder
ces dominate at high interaction propensities (Mann–Whitney U test).
der decreases progressively with respect to that of the full-length
role of disorder is more relevant in proteins lacking canonical
t have direct involvement in contacting RNA. Interaction propensities
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organ morphogenesis and embryonic development.
Co-expression and interaction propensity are features of
cell cycle control
At high interaction propensities (AUC > 95%; see Materials
and methods), the IC subset has more GO terms linked to
cell cycle control and housekeeping functions such as
nucleobase metabolism and purine biosynthesis (Figure 4
and Additional file 3: Table S1). In particular, mRNAs
interacting with co-expressed RBPs code for negative regu-
lators of cell proliferation and migration (translation,
signaling and metabolite utilization). We found a number
of tumor suppressors in the IC subset (AHRR, BAX,
BRMS1, CDKN1A, CDKN2A, CTBP1, DAB2IP, DKK3,
FLCN, FOXP1, GADD45G, GALR1, GTPBP4, HIC1,
IGFBP3, IRF8, KLF4, MEN1, MLH1, NF2, NR0B2, PARK2,
PAWR, PAX4, PAX5, PCGF2, PHB, PML, PPP1R1B,
PPP2R4, PTPRJ, PYCARD, RHOA, SIRT2, TFAP2A,
TNFAIP3, TRIM24, TSC2, TSG101, UCHL1). Interestingly,
90% of IC genes annotated with more functional categories
(381 out of 422) are listed in the gene index of the National
Institutes of Health’s Cancer Genome Anatomy Project
[40]. Terms associated with inhibition of cellular pathways
(especially the negative regulation of phosphorylation and
regulation of protein serine/threonine kinase activity) are
also more prevalent in the IC subset when immunochemis-
try data are used.
As mutations altering tumor suppression lead to aber-
rant proliferative events, we speculate that downregula-
tion of specific genes is a mechanism for preventing
indiscriminate cellular growth. In agreement with this
hypothesis, it has been reported that somatic loss of
function of the tumor suppressor tuberous sclerosis 2Figure 4 GO enrichment for interacting mRNA–RBP pairs correlated in
counted mRNA GO enrichment associated with different areas under the c
indicates the AUC values (number of interactions: 20,702,804 for AUC > 50%
cell cycle processes have more highly interacting mRNA–RBP pairs (AUC >
gene ontology; IC, interacting and co-expressed; RBP, RNA-binding protein(TSC-2) leads to the development of benign and malig-
nant lesions in the myometrium, kidney and other tis-
sues sharing common features such as a low rate of
renewal and defects in the mitochondrial respiratory
chain associated with oncogenesis [41,42]. This gene is
annotated in all the functional categories prevalent in
the IC subset. Intriguingly, it is predicted that TSC-2
mRNA interacts strongly with Nuclear Protein 5A
(NOP56). The interaction propensity is 175 correspond-
ing to an AUC of 99.5%. This protein is an essential com-
ponent of the splicing machinery [43] that is differentially
expressed in leiomyoma and downregulated in response
to hypoxia [44]. It is possible that hypoxia-dependent re-
pression of NOP56 expression [45-47] is a protective
mechanism against fast growth and potential tumor pro-
gression. Indeed, it has been reported that NOP56 and
TSC-2 are not differentially expressed in renal carcinomas
and oncocytomas [48,49] (ArrayExpress: E-GEOD-12090;
ArrayExpress: E-GEOD-19982), indicating loss of regula-
tion during malignant progression.
Based on these observations, we propose that down-
regulation of RBPs promoting the translation of dysfunc-
tional tumor suppressors can prevent indiscriminate
cellular growth and that loss of control can destine a
cell to malignancy (additional examples are reported in
Additional file 1).
Anti-expression and interaction propensity are features of
repressing processes
For AUC > 95%, the IA subset has more terms associated
with cell differentiation processes (for example, prox-
imal/distal pattern formation) as well as inflammation
(for example, positive regulation of isotype switching),
which are known to be tightly linked [50-52]. In fact, aexpression (IC subset). Using the catRAPID score distribution, we
urve (see Materials and methods). The color gradient (yellow to red)
, 10,351,402 for AUC > 75%, 2,070,280 for AUC > 95%). We found that
95%) that are correlated in expression. AUC, area under the curve; GO,
.
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EBI3/IL27) and stimulators of cytokine production
(CD28 and CD80CCR2/CD192) are in the subset. More-
over, a large fraction of entries is also linked to protein–
DNA complex assembly and regulation of transcription
initiation from RNA polymerase II promoter (Figure 5
and Additional file 3: Table S1). It has been shown that
94% of genes in IA enriched functional categories (124
out of 132) are listed in the annotated gene index of the
National Institutes of Health’s Cancer Genome Anatomy
Project [40]. Remarkably, terms clearly associated with
cell differentiation and inflammation (especially regula-
tion of embryonic development and B cell activation in-
volved in immune response) are more prevalent in the
IA subset when immunochemistry data are used.
IA genes share the common functional property of
regulating survival, growth and differentiation processes.
As RBPs play a crucial role in repressing gene expression
[53,54], IA associations could be involved in the regula-
tion of proliferative events. Indeed, adult tissues are
constantly maintained at the steady state [13] but a dra-
matic reawakening of growth, survival and differenti-
ation genes occur in either physiological conditions
(for example, wound healing [50]) or pathological pro-
gression to cancer [55].
In the IA set, we found YTHDC1 (YT521-B), which is
a ubiquitously expressed member of the novel RNA-
binding YTH-domain family [56]. YTHDC1 represses
gene expression by either sequestering splicing factors
or directly binding to transcripts [57-59] (Additional file
2: Figure S5A). Among the transcripts that we predict to
be potentially targeted by YTHDC1, we found several
proto-oncogenes or tumor-associated genes such as
RET, PRMT2, RARG and HOXA9 (RET: interactionFigure 5 GO enrichment for interacting mRNA–RBP pairs anti-correlat
we evaluated mRNA GO enrichment associated with different areas under
shows the AUC values (number of interactions: 20,702,804 for AUC > 50%, 1
differentiation processes are more prevalent in interacting mRNA–RBP pairs
the curve; GO, gene ontology; IA, interacting and anti-expressed; RBP, RNA-propensity = 166; PRMT2: interaction propensity = 209;
RARG: interaction propensity = 194; HOXA9: interaction
propensity = 165; all corresponding to an AUC of 99.5%).
In particular, alternatively spliced variants of PRMT2
were related to survival and the invasiveness of breast
cancer cells [60,61], while high expression of RARG and
HOXA9 has been observed in human hepatocellular
carcinomas and acute leukemia [62,63]. We hypothesize
that perturbation of the regulation by YTHDC1 of
potentially oncogenic genes such as RET, PRMT2, RARG
and HOXA9 could be involved in the pathogenesis of
related tumors. In fact, experimental studies support
the implications for YTHDC1 in cancer progression
with regard to angiogenesis, growth factor signaling,
immortalization, genetic instability, tissue invasion and
apoptosis [59,64,65].
Similarly, the translational silencer TIA-1, also re-
ported to induce mRNA decay [66-68], is predicted to
interact with the ubiquitously expressed NAP1L1 tran-
script (interaction propensity = 113 corresponding to an
AUC of 95%), consistent with iCLIP data for HeLa cells
(ArrayExpress: E-MTAB-432) [69] (Additional file 4:
Table S2). Deregulation of NAP1L1 expression has been
documented for several tumors such as small intestine
carcinoid neoplasia [70], neuroendocrine tumors [71],
ovarian cancer [72] and hepatoblastomas [73]. We
hypothesize that TIA-1 plays a fundamental role in the
post-transcriptional regulation of NAP1L1 and that alter-
ation of this regulatory process contributes to NAP1L1-
associated tumor development.
We note that repression of aberrant interactions can
be achieved by gene silencing, which prevents the poten-
tial stabilizing action of RBPs on specific transcripts
(Additional file 2: Figure S5B). For instance, the Nodaled in expression (IA subset). Using the catRAPID score distribution,
the curve (see Materials and methods). A color gradient (cyan to blue)
0,351,402 for AUC > 75%, 2,070,280 for AUC > 95%). We found that cell
(AUC > 95%) that are anti-correlated in expression. AUC, area under
binding protein.
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sion is associated with tumor progression [74]. Since
Nodal is a member of the Transforming Growth Factor
β (TGFB) superfamily and controls mesoderm formation
and axial patterning during embryonic development
[74], it is possible that Nodal interactions with specific
RBPs lead to pathogenesis in adult tissues. Our predic-
tions indicate that the transcript Nodal interacts
with a number of anti-expressed RBPs (ADD1, API5,
ARCN1, CANX, CAPRIN1, CCT6A, DKFZP434I0812,
GSPT1, HSP90AB1, PKM, PUF60, XRCC5, YTHDC1
and YWHAZ). Since the exact mechanism regulating
Nodal is at present unknown, we generated a list of pro-
tein partners that could be exploited for future experi-
mental studies (Additional file 5: Table S3).
Conclusions
Comparative expression studies provide important in-
sights into biological processes and can lead to the discov-
ery of unknown regulation patterns. While evolutionary
constraints on tissue-specific gene expression patterns
have been extensively investigated [7-9,75,76], the consti-
tutive regulation of RBP-mediated interactions is still
poorly understood [11,12]. It has been previously observed
that cellular localization and gene expression levels impose
stringent conditions on the physicochemical properties of
both protein and RNA sequences [77,78], but large-scale
computational analyses of constitutive RBP-mediated
regulatory networks have never been attempted before.
Our study shows for the first time that the integration of
in silico predictions [19] with ex vivo expression profile
data [6,34] can be used to discover distinct features of
RBP biological functions.
We observed an enrichment of unique and function-
ally related GO terms for RBP–mRNA pairs associated
with high interaction propensities and specific expres-
sion patterns. In our analysis, co-expression of interact-
ing mRNA–RBP pairs (IC set) is linked to regulation of
proliferation and cell cycle control, while anti-expression
(IA set) is a characteristic feature of survival, growth and
differentiation-specific processes. We do not exclude
that RBP–mRNA associations displaying poor inter-
action propensities (NIC and NIA sets) might have im-
portant evolutionary implications as spatiotemporal
separation and limited chemical reactivity could be ways
to avoid aberrant associations [55].
We found that RNA-binding proteins are enriched in
structurally disordered regions and that unfolded poly-
peptide fragments promote association with RNA mole-
cules at low interaction propensities. As disordered
proteins are highly reactive [37], it is reasonable to as-
sume that interaction with RNA needs to be tightly reg-
ulated to avoid cellular damage [39]. In this regard, our
results expand at the nucleic acid level what has beenpreviously observed for the general promiscuity of na-
tively unfolded proteins [38,79].
In conclusion, we hope that our study of protein–RNA
interaction and expression will be useful in the design of
new experiments and for further characterizing ribonu-
cleoprotein associations. A list of proposed interactions
and a server for new inquiries are available at the catRA-
PID express webpage [27].
Materials and methods
Prediction for LIN28B and HuR interactions
We performed a number of tests to assess the quality of
our calculations (see section on RNA-binding protein–
mRNA interaction propensity) using PAR-CLIP data
[31,33]. In this analysis, we used all the RNA interac-
tions present in our dataset (positive set: 285 sequences
for LIN28B and 579 for HuR) and, due to the unavail-
ability of non-bound RNAs, the full list of human tran-
scripts (negative set: 105,000 sequences).
For the significance of interaction predictions, we per-
formed Fisher’s exact test comparing the top 1% of pre-
dicted interactions with the remaining protein–RNA
associations (HuR: P = 10-8; LIN28B: P = 10-3). Fisher’s
exact test was computed using equal amounts (that is,
1% of the total interactions) of randomly extracted
negative subsets (HuR: P = 10-7; LIN28B: P = 0.0002;
Additional file 2: Figure S3).
For the significance of score distributions, we used
Student’s t-test to compare the score distribution of pos-
itives and negatives (HuR: P = 10-16; LIN28B: P = 10-4).
We also performed Student’s t-test using random extrac-
tions of negative subsets, each containing the same
number of RNAs as positives (LIN28B: P = 0.03; HuR:
P < 10-8; Student’s t-test).
Other statistical tests (receiver operating characteristics
and precision/recall curves) are discussed in Additional
file 1. The expression data for HuR and LIN28B were
taken from the original manuscripts [31,33] and processed
as indicated by the authors. The datasets were down-
loaded from GEO [29] (GSE29943) and ArrayExpress [80]
(E-GEOD-44615 and E-GEOD-44613).
mRNA dataset: Human BodyMap
The Human BodyMap (HBM) 2.0 contains expression
data generated using the Hiseq 2000 system and it has
expression profiles for a number of human tissues [22].
The HBM RNA sequencing (RNA-seq) data was down-
loaded from ArrayExpress [81] under accession number
E-MTAB-513. The final mRNA dataset contained 35,818
transcripts (11,584 genes) with expression levels for 14
human tissues (see section on RNA-binding protein–
mRNA expression). We considered all human cDNAs
from EnsEMBL release 68. Transcripts incompatible
with the catRAPID size restrictions (that is, 50 to 1,200
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filtered out. In the analysis, we evaluated different CD-
HIT [82] sequence similarity cutoff thresholds (see section
on Gene ontology analysis).RNA-binding protein dataset: Human Protein Atlas
We considered all the RBPs reported in two studies on
RBPs binding to mRNAs [1,2]. The initial dataset con-
sisted of 3,500 RBPs (832 genes). Proteins incompatible
with catRAPID’s size restrictions (that is, 50 to 750
amino acids) and above a CD-HIT [82] sequence simi-
larity cutoff of 75% were filtered out. Similarly, proteins
not present in the Human Protein Atlas (HPA) database
(version 11.0) [34] and not expressed in at least one tis-
sue were discarded. The final RBP (HPA) dataset con-
tained 612 proteins (491 genes) with expression levels
for 14 human tissues (see section on RNA-binding pro-
tein–mRNA expression). All protein sequences were re-
trieved from EnsEMBL release 68.RNA-binding protein dataset: Human BodyMap
As for RBPs in the HPA, filters on sequence size and
redundancy were applied. Proteins not present in the
Human BodyMap database (version 2.0) [6] were dis-
carded. The final RBP (HBM) dataset contained 1,156
proteins (543 genes) with expression levels for 14 human
tissues (see section on RNA-binding protein–mRNA
expression). All protein sequences were retrieved from
EnsEMBL release 68.RNA-binding protein–mRNA expression
We analyzed 14 human tissues for which both immuno-
histochemistry [34] and transcript abundances [6] were
available. At present, the Human Protein Atlas is the lar-
gest collection of protein abundance data available [34].
Transcripts in the mRNA dataset and proteins in the
RBP dataset were represented by vectors containing the
normalized relative abundance of the following tissues:
adrenal gland, brain, breast, colon, heart, kidney, liver,
lung, lymph, muscle, lymph node, ovary, prostate and
thyroid. For the immunohistochemistry data, the read-
outs ‘no’, ‘low’, ‘intermediate’ or ‘high’ expression were
transformed into numbers (0, 1, 2, 3) and subject to
Z-normalization per tissue. As for the transcript data,
the vectors were Z-normalized using the average and
standard deviation per tissue. For each RBP–mRNA
combination we computed the pairwise Pearson’s correl-
ation coefficient of the vectors. As shown in Additional
file 2: Figures S1 and S2, we observed the same trends
using immunohistochemistry [34] and RNA-seq data [6]
to estimate protein abundances in human tissues.RNA-binding protein–mRNA interaction propensity
We used catRAPID [19,20] to compute the interaction
propensity of each protein in the RBP dataset with each
transcript in the mRNA dataset. catRAPID predicts pro-
tein–RNA associations by estimating the interaction
propensity between amino acids and nucleotides using
secondary structure information, hydrogen bonding and
Van der Waals forces [19,20]. The approach was previ-
ously applied to predict associations between different
types of proteins and RNA molecules [21,23]. Although
each protein binds to distinct types of RNA structures
[83], we observe that the contribution of hairpin loops
accounts for 57% of the overall interaction propensity
[19]. The catRAPID web server is publicly accessible
from our webpage [84].
Protein–RNA interaction and expression
For a given protein, interacting (nint) and non-interacting
(nno-int) protein–RNA pairs were compared at different
AUCs (areas under the curve) of the interaction propen-
sity distribution. The enrichment in positively correlated
expression (Figure 2C) is calculated as:
enrichment co‐expressed interactionsð Þ
¼ nint r > rthð Þ−nno‐int r > rthð Þ
nno‐int r > rthð Þ ð1Þ
In Equation (1), the correlation coefficient r follows
the distribution of protein–RNA expression and the par-
ameter rth > 0 corresponds to an AUC spanning the
range 50% to 99.5% (Figure 2B).
Similarly, for negatively correlated expressions (Figure 2D):
enrichment anti‐expressed interactionsð Þ
¼ nint r < lthð Þ−nno‐int r < lthð Þ
nno‐int r < lthð Þ ð2Þ
In Equation (2), the parameter lth < 0 corresponds to
an AUC spanning the range 50% to 99.5% (Figure 2B).
Gene ontology analysis
For each area under the curve (AUC) of the catRAPID
score distribution (50% <AUC < 99.5%), we created four
subsets according to the correlation in tissue expression:
(1) IC subset: positively correlating and interacting genes
(expression correlation ≥ +0.7 and positive interaction pro-
pensities); (2) IA subset: negatively correlating and inter-
acting genes (expression correlation ≤ −0.7 and positive
interaction propensities); (3) NIC subset: positively correl-
ating and non-interacting genes (expression correlation
≥ + 0.7 and negative interaction propensities); (4) NIA
subset: negatively correlating and non-interacting genes
(expression correlation ≤ −0.7 and negative interaction
propensities). The expression correlation of |0.7| corre-
sponds to AUC= 95% of the statistical distribution, for
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We systematically applied conditional tests for GO term
over-representation in each subset using the GOStats
package (version 2.28.0) available from Bioconductor [85].
To assess the over-representation of a GO term in one
particular subset at a certain AUC, we considered five cri-
teria (Additional file 3: Table S1; Additional file 6: Table
S4; Additional file 2: Figure S6):
1. The GO term must be reported for more than two
genes.
2. The P value of the GO term must be significant
(P < 0.05) in the subset of interest and
non-significant (P > 0.1) in the others.
3. The enrichment must be conserved with respect to:
(a) the entire human transcriptome (that is,
including RNAs longer than 1,200 nucleotides and
independently of expression data), (b) the complete
set of analyzed genes (that is, including RNAs
shorter than 1,200 nucleotides and with available
expression) and (c) all genes under the same AUC
(that is, considering both interacting and non-
interacting pairs at the two tails of the distribution).
4. The P value of the GO term must be non-significant
(P > 0.1) in: (a) the complete set of analyzed genes
compared to the human transcriptome (significance
would indicate enrichment irrespective of the subset
assignment) and (b) the list of transcripts compatible
with catRAPID length requirements compared to
the human transcriptome (significance would
indicate length bias in the statistics; see section
on length bias statistics).
5. The enrichment must be conserved after sequence
redundancy reduction to the 80% identity threshold.Length bias statistics
Due to the conformational space of nucleotide chains,
prediction of RNA secondary structures is difficult when
RNA sequences are >1,200 nucleotides and simulations
cannot be completed on standard processors (2.5 GHz; 4
to 8 GB memory). To see whether GO enrichment is
biased by the catRAPID length restriction, we used a
hypergeometric test (see section on the RNA-binding pro-
tein–mRNA interaction propensity). If a GO term is
enriched in the length-restricted set, it is excluded a priori
from the analysis because genes annotated in that GO
term would be only selected for the length range. Thus,
we imposed that GO terms must be non-significant
(P > 0.1) in the length-restricted set of genes (see section
on gene ontology analysis). This condition ensures that
there is no bias due to length restrictions for any GO
term enriched in a particular subset (Additional file 3:
Table S1).Analysis of RNA-binding protein sequence disorder
The content of disordered regions in the RBP sequences
was computed using IUPred [36]. For each protein, we
extracted structurally disordered regions (IUPred score
higher than 0.4) and calculated their interactions against
the reference transcriptome. We compared the inter-
action propensities of each disordered region with that
of the full-length protein and assessed if there was an in-
crease or decrease of the interaction propensity score
(Figure 3A). The contribution of the disordered region
was evaluated using a Mann–Whitney U test, where a
significant increase (P < 0.05; H0 < H1) in the interaction
propensity score is associated with a positive contribu-
tion. From low to high interaction propensities, the con-
tribution of disorder decreases progressively with respect
to that of the full-length proteins (Figure 3A). The role
of disorder is more pronounced in proteins lacking
canonical RNA-binding domains, indicating that un-
structured regions have a direct involvement in contact-
ing RNA (Figure 3B).
Web server
catRAPID express [27] is a publicly available implemen-
tation of catRAPID [19,20], which is used to study the
relation between protein–RNA interaction propensity
and expression in Homo sapiens. The tool has two com-
ponents: (1) catRAPID predictions of protein–RNA
interaction and (2) the computation of correlation using
protein and RNA expression profiles [6,34]. A descrip-
tion of how catRAPID makes predictions can be found
in the Documentation, Tutorial and Frequently Asked
Questions (FAQs) on the webpage. Expression profiles of
the RBP dataset and mRNA dataset are assigned respect-
ively to input proteins and RNA using a homology-
based criterion (ten top-ranked proteins with a BLAST
[86] e ≤ 0.01 and ≥75% whole sequence similarity; ten
top-ranked transcripts with a BLAST e ≤ 0.01 and ≥95%
whole sequence similarity). Sequence similarity is evalu-
ated using the Needleman–Wunsch algorithm [87].
Additional files
Additional file 1: Additional materials and methods.
Additional file 2: Figure S1. With respect to non-interacting protein–RNA
pairs, non-correlated protein–RNA expression does not show enrichment
using (A) RNA and (B) protein expression. Areas under the curve (AUCs)
were used to select the same number of interacting/non-interacting and
positively/negatively expressed protein–RNA pairs for the analysis.
Figure S2. Protein–RNA interaction and expression (immunohistochemistry
expression data). (A) With respect to non-interacting protein–RNA pairs,
predicted associations had enriched positively correlated expression.
(B) Compared to non-interacting protein–RNA pairs, predicted associations
had enriched negatively correlated expression. Figure S3. P value
distribution for HuR and LIN28B predictions. We compared P values
(Fisher’s exact test) for the catRAPID predictions for HuR and LIN28B
RNA interactions (red arrow) using balanced bootstrap resampling
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positive subset). The predicted interactions differ significantly from
random associations. Figure S4. Receiver operating characteristic (ROC)
and precision/recall (PR) curves for HuR and LIN28B predictions. We
evaluated changes in the ROC and PR curves for the catRAPID predictions
for the (A) HuR and (B) LIN28B RNA interactome for random samples using
several ratios of positive and negative associations (pos/neg ratios).
Figure S5. Examples of protein–RNA anti-expression scenarios. (A) We
propose that YTHDC1 represses the expression of tumor-associated genes
by destabilizing mRNAs. (B) Nodal expression in adult tissues is associated
with tumor progression, which might be due to transcript stabilization.
Figure S6. Nested representation of gene sets used in GO enrichment
analysis. Figure S7. Changes in transcript and gene counts after sequence
redundancy reduction. The mRNA database comprises 35,818 transcripts
(11,584 genes). After redundancy filtering, the mRNA database is reduced to
33,936 transcripts (11,483 genes) at 95% sequence identity threshold; 32,700
transcripts (11,406 genes) at 90%; 31,287 transcripts (11360 genes) at 85%
and 29,673 transcripts (11,317 genes) at 80%.
Additional file 3: Table S1. mRNA GO-term enrichment analysis of
interacting mRNA–RBP pairs (P values). Every GO term has been tested
for over-representation for each subset (IC, IA, NIC and NIA) with respect
to the human transcriptome, the complete set of analyzed genes
(analyzed mRNA set) and the analyzed genes with the same AUC (relative
AUC subset). Statistical control for the biased over-representation of
GO terms in the complete set of analyzed genes and in a catRAPID
length-restricted set of genes was used for the human transcriptome
(see Materials and methods). Significant P values for the IC and IA subsets
are shown in red. GOBP, gene ontology biological process; GOCC, gene
ontology cellular component; GOMF, gene ontology molecular function;
IA, interacting and anti-correlated in expression; IC, interacting and
correlated in expression; NIC, not interacting and correlated in expression;
Seq%id, sequence identity threshold used for redundancy reduction.
Additional file 4: Table S2. NAP1L1 read counts from TIA-1 iCLIP data.
The count of reads mapping into the NAP1L1 gene and the relative
cumulative distribution functions (cdf) are reported from the iCLIP
experiment for controls and replicates of the TIA-1 protein [20]. The read
count cdf was estimated after removal of genes with zero counts.
Additional file 5: Table S3. Nodal anti-expressed interacting (IA) RBPs.
Additional file 6: Table S4. mRNA GO-term enrichment analysis of
interacting mRNA–RBP pairs (IC and IA gene counts are reported). Every
GO term has been tested for over-representation in the IC and IA subsets
with respect to the human transcriptome, the complete set of analyzed
genes (analyzed mRNAs set) and the analyzed genes under the same
AUC (relative AUC subset).GOBP, gene ontology biological process; GOCC,
gene ontology cellular component; GOMF, gene ontology molecular
function; IA, interacting and anti-correlated in expression; IC, interacting
and correlated in expression; Seq%id, sequence identity threshold used
for redundancy reduction.
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